IRAK4 and rheumatoid arthritis: PF-06650833, an oral small-molecule IRAK4 inhibitor, showed favorable safety and pharmacokinetic profiles in phase I trials, and was subsequently evaluated in a phase IIb trial in RA patients with moderate to severe disease refractory to methotrexate (NCT02485769, NCT02996500) [57, 318].